Pulse Biosciences, Inc.
PLSE · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.95 | 0.66 | -0.23 | -4.22 |
| FCF Yield | -1.27% | -1.26% | -0.90% | -0.85% |
| EV / EBITDA | -48.52 | -53.72 | -45.44 | -74.88 |
| Quality | ||||
| ROIC | -17.99% | -14.20% | -16.37% | -15.61% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.67 | 0.67 | 0.81 | 0.47 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 4.84% | -47.50% | -1.49% | -7.57% |
| Safety | ||||
| Net Debt / EBITDA | 5.19 | 6.14 | 5.46 | 5.29 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 5.24 | 9.43 | 0.00 | 0.00 |
| Cash Conversion Cycle | -907.08 | -744.17 | -180.97 | -582.13 |